Vaccinex, Inc. Announces the First Patient Treated in a Phase Ib/II Combination Study with Anti-Semaphorin 4D Antibody, VX15/2503, and Avelumab in Non-Small Cell Lung Cancer Patients (CLASSICAL – Lung)
October 26, 2017 10:23 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Vaccinex Inc. today announced the dosing of the first patient in a Phase Ib/II study of VX15/2503, an investigational humanized anti-semaphorin 4D...
eFFECTOR Therapeutics Initiates Dosing in Phase 2 Combination Trial of eFT508 and Avelumab in Microsatellite Stable Colorectal Cancer
October 04, 2017 10:00 ET
|
EFFECTOR Therapeutics
SAN DIEGO, Oct. 04, 2017 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators (STRs) for the treatment of cancer, today announced it has...
Vaccinex Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, to Evaluate the Combination of VX15/2503, and Avelumab in Non-Small Cell Lung Cancer
October 06, 2016 09:45 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc. announced today it has entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, to evaluate VX15/2503, an...